CSHNs represent a suitable approach for the treatment of many life-threatening diseases, especially cancer treatment, as they allow the delivery of more than one therapeutic molecule in the same carrier, depending on their core-shell structure. Considering the unique morphology, biocompatibility, low toxicity, and high encapsulation capacity of these hybrid nanoscale particles with core-shell structure, and especially the possibility to modify the surface for active targeting, studies with CSHNs in the field of various therapeutic applications have the potential to achieve breakthroughs in the future.